✉ Email this page to a colleague
« Back to Dashboard
Rilotumumab is an investigational drug.
There have been 11 clinical trials for Rilotumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Stomach Neoplasms, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Southwest Oncology Group.
There are fourteen US patents protecting this investigational drug and two hundred and sixty-six international patents.
Recent Clinical Trials for Rilotumumab
|A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer||Amgen||Phase 3|
|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||National Cancer Institute (NCI)|
|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||Southwest Oncology Group|
Top disease conditions for Rilotumumab
Top clinical trial sponsors for Rilotumumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Rilotumumab||See Plans and Pricing||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||See Plans and Pricing|
|Rilotumumab||See Plans and Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Plans and Pricing|
|Rilotumumab||See Plans and Pricing||Cancer treatment with c-met antagonists and correlation of the latter with HGF expression||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|Rilotumumab||See Plans and Pricing||Method for predicting efficacy of c-Met inhibitor||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||See Plans and Pricing|
|Rilotumumab||See Plans and Pricing||Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||See Plans and Pricing|
|Rilotumumab||See Plans and Pricing||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Rilotumumab||Canada||CA2900764||2033-02-08||See Plans and Pricing|
|Rilotumumab||European Patent Office||EP2954056||2033-02-08||See Plans and Pricing|
|Rilotumumab||Hong Kong||HK1218930||2033-02-08||See Plans and Pricing|
|Rilotumumab||Japan||JP2016509014||2033-02-08||See Plans and Pricing|
|Rilotumumab||World Intellectual Property Organization (WIPO)||WO2014124326||2033-02-08||See Plans and Pricing|
|Rilotumumab||Australia||AU2013220749||2032-02-15||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|